Cockroach T Cell Epitope Peptides for Allergy Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Cockroach allergies lack effective immunological understanding and therapeutic options, particularly regarding T cell responses, which are crucial for the development and treatment of allergic reactions and asthma exacerbations.
Innovation Solution
Development of novel Cockroach peptides and proteins, including specific amino acid sequences, that modulate immune responses, induce immunological tolerance, and potentially treat allergic reactions by targeting T cell responses and allergen-specific antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional allergen-based treatments are used for Cockroach allergies, then IgE-mediated humoral responses are targeted, but T cell responses remain unaddressed and immunopathology persists
Solution Approach 1:
The patent segments the complex Cockroach allergen into specific T cell epitope peptides (e.g., Bla g 1 peptides of 15-30 amino acids). This segmentation allows targeted delivery to T cells while maintaining the ability to address the unaddressed T cell response component, thereby improving therapeutic efficacy without overwhelming complexity
Solution Approach 2:
The patent introduces dendritic cells as intermediaries that process and present the segmented epitope peptides to T cells. This intermediary mechanism bridges the gap between conventional allergen treatment and T cell modulation, enabling targeted T cell response modification while maintaining a manageable immunological approach
2Loss of information
If early life exposure to Cockroach allergens occurs, then allergic sensitization develops with strong correlation to asthma incidence, but understanding of T cell involvement remains insufficient
Solution Approach 1:
The patent applies preliminary action by exposing subjects to specific T cell epitope peptides before full allergen exposure or during early sensitization phases. This preliminary exposure to controlled epitopes aims to induce tolerogenic T cell responses that prevent subsequent allergic sensitization and asthma development, addressing the knowledge gap while preventing harm
Solution Approach 2:
The patent converts the harmful early life allergen exposure that causes sensitization into a beneficial approach by using controlled exposure to specific T cell epitopes. This controlled epitope exposure aims to induce regulatory T cell responses that prevent allergic sensitization, transforming the problematic early exposure scenario into a protective intervention
3Ease of operation
If Specific ImmunoTherapy is administered, then clinical efficacy may be achieved, but the role of T cell responses in efficacy remains unexplored
Solution Approach 1:
The patent changes the parameters of immunotherapy by shifting from whole allergen administration to specific T cell epitope peptides (15-30 amino acids). This parameter change enables better characterization of T cell responses in terms of frequency, phenotype, and specificity, while maintaining ease of operation through standardized peptide formulations
4Quantity of substance
If Cockroach allergen proteins are used for treatment, then IgE responses are modulated, but T cell epitope definition remains undefined for all Bla g allergens
Solution Approach 1:
The patent segments the complete Cockroach allergen proteins into overlapping peptides of 15-30 amino acids, systematically covering all Bla g allergens (Bla g 1, 2, 4, 5, 6, 7). This segmentation approach enables comprehensive T cell epitope identification across all allergens while maintaining adequate protein coverage for immunological response
Solution Approach 2:
The patent changes the analytical parameters by using HLA binding affinity predictions and T cell assay results to identify epitopes. This parameter change enables precise T cell epitope definition for all Bla g allergens, transforming the undefined state into a characterized set of immunodominant peptides
Data Source
AI summary
The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.